Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Enterprise Value (2017 - 2025)

Aclaris Therapeutics has reported Enterprise Value over the past 9 years, most recently at -$90.8 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$90.8 million for Q4 2025, up 20.11% from a year ago — trailing twelve months through Dec 2025 was -$90.8 million (up 20.11% YoY), and the annual figure for FY2025 was -$90.8 million, up 20.11%.
  • Enterprise Value for Q4 2025 was -$90.8 million at Aclaris Therapeutics, up from -$95.9 million in the prior quarter.
  • Over the last five years, Enterprise Value for ACRS hit a ceiling of -$90.8 million in Q4 2025 and a floor of -$248.6 million in Q2 2022.
  • Median Enterprise Value over the past 5 years was -$127.9 million (2024), compared with a mean of -$151.4 million.
  • Biggest five-year swings in Enterprise Value: crashed 258.29% in 2021 and later skyrocketed 58.46% in 2023.
  • Aclaris Therapeutics' Enterprise Value stood at -$191.4 million in 2021, then decreased by 13.67% to -$217.6 million in 2022, then soared by 45.26% to -$119.1 million in 2023, then increased by 4.63% to -$113.6 million in 2024, then rose by 20.11% to -$90.8 million in 2025.
  • The last three reported values for Enterprise Value were -$90.8 million (Q4 2025), -$95.9 million (Q3 2025), and -$99.8 million (Q2 2025) per Business Quant data.